conray-meglumin 282 mg i/ml injektioneste
astra tech ab - happo iotalamicum - injektioneste - 282 mg i/ml - jotalaamihappo
conray 400 mg i/ml injektioneste
astra tech ab - happo iotalamicum - injektioneste - 400 mg i/ml - jotalaamihappo
conray 200 mg i/ml injektioneste
astra tech ab - happo iotalamicum - injektioneste - 200 mg i/ml - jotalaamihappo
contralum emulsiovoide
hermal kurt herrmann - 3,4-dimetoksi-phenylglyoxylacid -, natrium-suolaa,2,2'-dihydroksi-4,4'-dimethoxybenzophenonum - emulsiovoide - muut pehmentävät ja suojaavat aineet
contralac vet 0.5 mg tabletti
virbac s.a. virbac s.a. - metergolinum - tabletti - 0.5 mg - metergoliini
contralac vet 2 mg tabletti
virbac s.a. virbac s.a. - metergolinum - tabletti - 2 mg - metergoliini
contrall 5 mg / 12.5 mg tabletti, kalvopäällysteinen
merck kgaa - hydrochlorothiazidum,bisoprololi fumaras - tabletti, kalvopäällysteinen - 5 mg / 12.5 mg - bisoprololi ja tiatsidit
contrall 10 mg / 25 mg tabletti, kalvopäällysteinen
merck kgaa - hydrochlorothiazidum,bisoprololi fumaras - tabletti, kalvopäällysteinen - 10 mg / 25 mg - bisoprololi ja tiatsidit
mounjaro
eli lilly nederland b.v. - tirzepatide - diabetes mellitus, tyyppi 2 - diabeetilla käytettävät lääkkeet - mounjaro is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications- in addition to other medicinal products for the treatment of diabetes. for study results with respect to combinations, effects on glycaemic control and the populations studied, see sections 4. 4, 4. 5 ja 5.
leqvio
novartis europharm limited - inclisiran - hypercholesterolemia; dyslipidemias - lipidimodifioivat aineet - leqvio is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin, oralone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.